Human Papillomavirus HPV Pathogenesis Diagnosis and Vaccination

Video overview

This Osmosis video explains how human papillomaviruses infect human epithelial cells, how viral proteins E6 and E7 disrupt tumor suppressor pathways, the spectrum from benign warts to carcinomas, and how infections are diagnosed and prevented through screening and vaccination. It also covers treatment options for removing lesions and boosting immune response.

Key insights

• HPV types target specific epithelial cells and can cause warts or cancer depending on type.
• Two viral genes E6 and E7 dysregulate p53 and RB pathways, driving uncontrolled cell growth.
• Diagnosis relies on molecular testing and cervical screening such as Pap tests, with visualization when needed.
• Prevention via HPV vaccination before exposure and safer sexual practices reduces risk of high risk HPV associated cancers.

HPV Overview and Biology

Human papillomaviruses are non enveloped DNA viruses that specifically infect human epithelial cells. There are more than 100 HPV types, each with preferred sites such as cutaneous skin or mucous membranes in the respiratory tract and anogenital regions. In many infections, HPV remains subclinical or asymptomatic, but certain high risk types are associated with precancerous lesions and carcinomas in the cervix or other epithelia. The virus gains access through abrasions, then can replicate with or without integrating into the basal cell genome. Central to HPV driven oncogenesis are two viral genes E6 and E7 that alter host tumor suppressor pathways, notably p53 and retinoblastoma protein RB, promoting dysregulated epithelial cell replication and lesion formation.

Mechanisms of Infection and Disease Progression

After gaining access to basal epithelial cells, HPV can replicate in a manner that disrupts normal cell cycle control. E6 and E7 proteins interfere with tumor suppressor signaling, leading to uncontrolled growth, cellular dysplasia, and potential transformation into carcinomas if progression cofactors are present. In some HPV infections, koilocytes with irregular nuclei appear and precancerous changes can evolve as the basement membrane is breached. The likelihood of progression to cancer depends on HPV type, cofactors such as tobacco use, immunosuppression, and prior radiation exposure, with high risk types 16 and 18 being especially associated with cervical and other cancers.

Clinical Manifestations and Visual Diagnosis

Infections can be asymptomatic or cause benign warts on the skin or mucous membranes. Cutaneous warts on hands, feet, or facial areas are usually non painful, whereas mucosal infections can cause respiratory papillomatosis or genital warts characterized by cauliflower like surfaces. In genital infections, multiple warts may appear on external genitalia or within the cervix, vulva, vagina or penis. Laryngeal HPV infections are a major cause of HPVs associated papillomatosis which can affect voice and breathing. Definitive diagnosis often requires molecular testing of biopsied cellular DNA or RNA, and regular cervical Pap tests or acetic acid tests after age 21 help detect subclinical disease. Endoscopy may be used to visualize upper respiratory tract involvement when suspected.

Diagnosis and Treatment

Definitive HPV diagnosis relies on detection of viral DNA or RNA in infected cells. Visualizing epithelial changes may involve endoscopy, Pap smears, or acetic acid tests, but molecular testing remains essential. Treatments focus on removing warts or precancerous lesions using salicylic acid formulations, cryotherapy with liquid nitrogen, laser therapy, or surgical excision. For recurrent infections, immune modulators may be used to boost host immunity so the infection clears naturally. Most infections, especially low risk HPV types and in younger individuals, resolve spontaneously over time, underscoring the role of immune response in clearance.

Prevention Strategies

Prevention is best achieved by immunization before first exposure to the virus, along with limiting contact with potentially infected individuals and using condoms. The HPV vaccine targets high risk types including 16 and 18. Vaccination reduces the risk of cervical and several other HPV related cancers and diseases. Routine screening with Pap tests remains critical for early detection and improving outcomes even in vaccinated populations.

Summary

Human papillomaviruses are DNA viruses that infect epithelial surfaces. E6 and E7 oncoproteins disrupt p53 and RB pathways, enabling dysregulated growth and, in some cases, progression to cancer. Diagnosis combines molecular testing with screening and endoscopic visualization as needed. Treatments emphasize lesion removal and immune support, while vaccination provides strong protection against many high risk HPV types. Regular screening and vaccination together form a powerful strategy to reduce HPV related cancer burden.